R&D channel feed

Nu­va­tion Bio shares piv­otal Chi­na da­ta for can­cer drug from An­Heart buy­out

Last year
China

AS­CO ab­stracts are out, with da­ta for AD­Cs, Nim­bus' next-gen I/O drug and more

Last year
Pharma

UK biotech re­vives for­mer Ky­owa Kirin can­cer drug for Ep­stein-Barr-dri­ven dis­eases

Last year
Startups

As­traZeneca taps more Chi­na-de­rived tech with $19M can­cer deal for Nona an­ti­bod­ies

Last year
Deals

Cri­net­ic­s' stock jumps fol­low­ing promis­ing Ph2 da­ta in four pa­tients with rare ge­net­ic dis­or­der

Last year

Ot­su­ka ter­mi­nates Alzheimer's ag­i­ta­tion drug af­ter failed Phase 3

Last year

Dai­ichi Sankyo to open two new re­search sites in Cam­bridge and Mu­nich this year

Last year

Oral drug shows promise in di­a­bet­ic mac­u­lar ede­ma as biotech touts an­ti-VEGF in­jec­tion al­ter­na­tive

Last year

NIH drafts pol­i­cy on en­sur­ing ac­cess to new drugs fund­ed by tax­pay­ers

Last year
FDA+

As­traZeneca counts on ‘dif­fi­cult-to-copy’ ther­a­pies for big 2030 goal and be­yond

Last year
Pharma

Sanofi, Ope­nAI, For­ma­tion Bio an­nounce AI drug de­vel­op­ment part­ner­ship

Last year
Deals
AI

FDA lifts par­tial clin­i­cal hold on Lari­mar’s Friedre­ich’s atax­ia treat­ment

Last year
FDA+

GSK says long-act­ing asth­ma treat­ment clears two Phase 3 stud­ies

Last year

UK biotech rais­es £35M to de­vel­op sol­id tu­mor drugs based on ma­chine learn­ing

Last year
Financing

Dyne Ther­a­peu­tics sharp­ens case for two mus­cle dis­ease ther­a­pies with up­dat­ed da­ta 

Last year

As­traZeneca, Am­gen tout Phase 2a Tezspire da­ta in COPD ahead of Dupix­ent de­ci­sion

Last year

Gilead­'s rare liv­er dis­ease drug im­proves symp­toms in an­oth­er Phase 3 study ahead of FDA de­ci­sion

Last year

FDA re­jects liv­er can­cer drug com­bo, shares of Ko­re­an biotech tank

Last year
FDA+

Eras­ca re­vamps pipeline, lay­ing off staff as it li­cens­es can­cer drugs from Chi­na and nabs $160M

Last year
Deals

Bay­er de­tails da­ta from two Phase 3 tri­al wins for menopause symp­tom drug

Last year

Roche was in 'ad­vanced' talks to out-li­cense its An­gel­man syn­drome drug, but po­ten­tial part­ner with­drew

Last year
Deals
Pharma

Bio­gen CEO Viehbach­er un­daunt­ed by Lil­ly's im­pend­ing Alzheimer's ther­a­py, say­ing it will ‘ex­pand’ mar­ket

Last year

Pfiz­er, Arv­inas’ breast can­cer drug com­bo keeps mo­men­tum af­ter Phase 1b up­date

Last year

Bio­gen and Io­n­is aban­don ALS drug af­ter dis­ap­point­ing ear­ly-stage tri­al

Last year
First page Previous page 44454647484950 Next page Last page
A service from the Financial Times